Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-50644 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CALCRL Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- The antibody detects endogenous levels of total CALCRL / CRLR protein.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 2.7 mg/mL
- Storage
- -20°C
Submitted references Neuropeptide-induced modulation of carcinogenesis in a metastatic breast cancer cell line (MDA-MB-231(LUC+)).
Gutierrez S, Boada MD
Cancer cell international 2018;18:216
Cancer cell international 2018;18:216
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of CALCRL was performed by loading (from left to right): Human lung cancer tissue lysates (40µg) on to a 8% SDS-PAGE gel. Proteins were transferred to a membrane and the membrane was probed with a CALCRL antibody (Product # PA5-50644) at a 1/550 dilution for 40 seconds, followed by a secondary antibody at 1/8000.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of CALCRL in paraffin embedded Human thyroid cancer tissue using CALCRL Polyclonal Antibody (Product # PA5-50644) at a 1:40 dilution.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 3 NP time-dependent induced changes in the expression of neurokinin and CGRP receptors in the MDA-MB-231 LUC+ cells homogenate using Western blot analysis. a Representative immunoblots for NK1R (~ 75-100 kDa), NK2R (~ 44 kDa), RAMP1 (~ 17 kDa), CALCRL (~ 45-55 kDa) and GAPDH (~ 37 kDa) from cells homogenates. b Changes in the expression of NK-1R, NK-2R, RAMP1 and CALCRL (first, second, third and fourth panel, respectively) in human metastatic breast cancer cells at 24-72 h after NP treatment. Three independent experiments were performed. Data represent NK-1R, NK-2R, RAMP1 and CALCRL/GAPDH ratio, normalized to the mean value for the corresponding control group at 24, 48 or 72 h (punctuated line). Data are presented as median (numbers and horizontal line) with boxes representing the 25 and 75 percentiles, * P < 0.05; ** P < 0.01; *** P < 0.001 compared to control or NP treatment group
